Introduction
Fifteen years ago, it became evident that genomic rearrangements and gene dosage effects, rather than the classical model of coding region DNA sequence alterations, could be responsible for a common, autosomal dominant, adult-onset neurodegenerative trait-Charcot-Marie-Tooth neuropathy type 1A (CMT1A; Lupski et al., 1991; Raeymaekers et al., 1991; Lupski et al., 1992) . With the identification of the CMT1A duplication and its reciprocal deletion causing hereditary neuropathy with liability to pressure palsies (HNPP), the demonstration that PMP22 copy-number variation (CNV) could cause inherited disease in the absence of codingsequence alterations, was initially hard to fathom. How could such subtle changes-three copies of the normal ''wild-type'' PMP22 gene rather than the usual twounderlie neurologic disease?
Nevertheless, it has become apparent during this last decade and a half that neurodegeneration can represent the outcome of subtle mutations acting over prolonged time periods in tissues that do not generally regenerate, regardless of exact molecular mechanism. This concept has revealed itself through (1) conformational changes causing prion disease, (2) the inability to degrade accumulated toxic proteins in amyloidopathies, a-synucleinopathies, and polyglutamine expansion disorders, and (3) alteration in gene copy number and/or expression level through mechanisms such as uniparental disomy (UPD), chromosomal aberrations (e.g., translocations), and submicroscopic genomic rearrangements including duplications, deletions, and inversions.
Currently, structural variation of the human genome is commanding a great deal of attention Freeman et al., 2006) . In the postgenomic era, the availability of human genome sequence for genome-wide analysis has revealed higher-order architectural features (i.e., beyond primary sequence information) that may cause genomic instability and susceptibility to genomic rearrangements. Nevertheless, it is perhaps less generally appreciated that any two humans contain more base-pair differences due to structural variation of the genome than resulting from single-nucleotide polymorphisms (SNPs; Rendon et al., 2006) . De novo genomic rearrangements have been shown to cause both chromosomal and Mendelian disease, as well as sporadic traits (Lupski, 2006; Lupski and Stankiewicz, 2006) , but our understanding of the extent to which genomic rearrangements, gene CNV, and/or gene dosage alterations are responsible for common and complex neurological traits remains rudimentary.
Interestingly, several neurodegenerative and neurodevelopmental disorders are now known to be caused by disparate recurrent and nonrecurrent genomic rearrangements that are mediated or stimulated by complex regional genomic architecture occurring throughout the human genome. These genomic disorders include peripheral (PNS) and central (CNS) nervous system neuropathies, well-recognized syndromes with characteristic behavioral or neurocognitive phenotypes, and also a growing number of psychiatric illnesses. Thus, there is indisputable evidence that CNV can play a role in the pathogenesis of neurodevelopmental and neurodegenerative disorders. In this review, we will discuss the mechanisms of genomic rearrangements and CNV, then focus on selected disorders that involve neurodevelopmental, neurodegenerative, and psychiatric symptoms in greater detail. In addition, we will discuss the role of CNV in normal human variation and hypothesize that genomic rearrangements may underlie not only neurologic diseases, but also complex traits. Finally, we speculate that gene CNV due to structural alteration may be responsible for both normal and abnormal behavioral phenotypes.
Mechanisms of Genomic Rearrangements
Genomic rearrangements include duplications, deletions, and inversions of unique genomic segments at specific regions, as well as translocations, marker chromosomes, isochromosomes, and other complex rearrangements (Lupski, 1998; Emanuel and Shaikh, 2001; Stankiewicz and Lupski, 2002) . These rearrangements are not random events but instead reflect the involvement of higher-order architectural features of the human genome.
The architectural features that appear to render genomic regions susceptible to rearrangement include region-specific repeat sequences, or low-copy repeats (LCRs). LCRs can contain one or multiple genes, pseudogenes, gene fragments, retroviral sequences, *Correspondence: jlupski@bcm.tmc.edu regulatory regions, or other paralogous segments (Lupski, 1998) and are characterized as repeat sequences, as opposed to highly repetitive sequences (i.e., long or short interspersed elements, retrotransposons, satellite DNA, centromeres , and telomeres) that were initially identified on the basis of reassociation kinetics (Britten and Davidson, 1976) . LCRs are often found in pericentromeric and subtelomeric regions of human chromosomes (Eichler et al., 1999) , but they may be found in interstitial regions as well. LCRs are sometimes referred to as segmental duplications or duplicons (Bailey et al., 2001) , although the latter term can be ambiguous when greater than two copies of the repeated segment exist. The size, relative orientation, distance between copies, and shared percent identities of the LCRs are factors that render the genomic region susceptible to rearrangement and may influence the type of rearrangement which occurs.
Rearrangements are classified as either recurrent or nonrecurrent, depending on whether the same rearrangement can be identified in unrelated individuals, and can be either constitutional (germline) meiotic events or de novo somatic events confined to a subset of cells (Shaffer and Lupski, 2000) . In general, recurrent rearrangements, or those of common size and having clustered breakpoints, most frequently result from a mechanism of nonallelic homologous recombination (NAHR) between region-specific LCRs (Lupski, 1998; Stankiewicz and Lupski, 2002;  Figure 1 ). In general, genomic architectural features favorable for rearrangements to occur via NAHR and cause gene CNVs consist of LCRs (1) >10 kb in size, (2) with >97% sequence identity, (3) directly oriented, (4) within 5 Mb of each other, and (5) located on the same chromosome (i.e., intrachromosomal; Lupski, 1998) . Establishing a mechanism for these rearrangements and delineating the ''rules'' governing their occurrence enables an informed approach for designing targeted assays interrogating such regions of predicted genomic instability Sharp et al., 2006) . Nonrecurrent rearrangements, or those for which breakpoints do not cluster and that are generally different in size between families, can result from either NAHR or nonhomologous end-joining (NHEJ) mechanisms (Inoue et al., 2002; Shaw and Lupski, 2005 ). Whereas LCRs have been shown to mediate recurrent and nonrecurrent recombinational repair by NAHR, it is postulated that LCRs may instead stimulate, but not necessarily mediate, nonrecurrent recombinational repair by the error-prone mechanism of NHEJ (Inoue et al., 2002; Stankiewicz et al., 2003; Shaw and Lupski, 2005; Lee et al., 2006a) . However, the precise mechanism by which this stimulation may occur remains to be elucidated.
Neurodevelopmental Disorders
Neurodevelopmental disorders are generally characterized by neurological signs which occur during a stage of rapid nervous system development-from the point of conception to early adulthood. These disorders encompass a variety of signs and symptoms including a range of cognitive impairment from learning disability to mental retardation, abnormal behaviors, sensory impairment, seizures, and/or neuromotor dysfunction. Neurodevelopmental disorders can be either genetic (metabolic, chromosomal, or structural) or acquired. Herein, we will focus on several neurodevelopmental disorders caused by genomic rearrangement and CNV (Table 1) . Williams-Beuren Syndrome and Its Reciprocal Duplication It is likely that specific genes contained within chromosome 7q11.23 are dosage sensitive and play a role in human language and visuospatial proficiency. A recurrent microdeletion of w1.6 Mb results in CNV of 28 genes, causing Williams-Beuren syndrome (WBS; OMIM #194050). Interestingly, the expression levels of genes flanking but not included in the deletion in WBS patients also have been found to be reduced (Merla et al., 2006) , suggesting a potential dosage-sensitive role of genes adjacent to the commonly deleted region that may contribute to or modify other aspects of the WBS phenotype. The reciprocal duplication of the same region, which was only recently reported , causes a clinically distinct disorder dominated by speech delay.
Individuals with WBS exhibit a combination of striking behavioral abnormalities and a characteristic neurocognitive profile. WBS patients present with a distinctive (C) Different complex rearrangements are generated depending on the combination of LCRs that participate in the NAHR event. Colored arrows represent LCRs. Recombination is signified by ''X.'' Gradiently shaded arrow represents a unique directional segment of DNA, and an example of CNV of a unique segment (i.e., gene) is shown in the products of (A).
facial phenotype, a spectrum of learning disability and/or mental retardation, prominently featuring severe visuospatial construction deficits, and attention-deficit hyperactivity disorder (ADHD; Mervis et al., 2000; Morris et al., 2003; Leyfer et al., 2006) . Patients with WBS tend to have neurologic and sensorineural difficulties such as hyperacusis (Chapman et al., 1996; Marler et al., 2005) in addition to CNS structural abnormalities (Jernigan and Bellugi, 1990; Pober and Filiano, 1995; Mercuri et al., 1997; Schmitt et al., 2001; Galaburda et al., 2002; Tomaiuolo et al., 2002 ). Their behavior is described as outgoing and loquacious with high-level verbal abilities that can make their mental capabilities appear greater than shown by formal IQ testing. Conversely, the phenotype seen in a small number of individuals reported to have the reciprocal duplication includes a severe delay in expressive speech and language, developmental delay, growth retardation, mental retardation, and a behavioral phenotype (J. Berg et al., personal communication; Somerville et al., 2005; Kriek et al., 2006) . The WBS deletion, and presumably the reciprocal duplication, is caused by meiotic NAHR (Urban et al., 1996) mediated by highly homologous flanking LCR structures (Peoples et al., 2000; Bayé s et al., 2003) . Inversion of the same segment has been found as a polymorphic variant in 33% of the parents of WBS patients, in some atypical WBS patients (27%), and also in some individuals with mental retardation and features associated with WBS (Osborne et al., 2001) . Interestingly, inversion polymorphisms at this and other loci appear to be associated with susceptibility to germline deletion (Osborne et al., 2001; Giglio et al., 2002; Gimelli et al., 2003; Koolen et al., 2006; Lupski, 2006; Sharp et al., 2006; Shaw-Smith et al., 2006) . 15q11-q13 Rearrangements in Angelman and Prader-Willi Syndromes, idic(15), and dup(15) The 15q11-q13 region has been shown to undergo genomic rearrangement at a relatively high frequency. A recurrent w4 Mb deletion of this region is responsible for most cases of Angelman (AS; OMIM #105830; Williams et al., 1995) and Prader-Willi (PWS; OMIM #176270; Bittel and Butler, 2005) syndromes, depending on the parent of origin for the deletion. Whereas AS patients have more severe cognitive and neurological impairment and seizures, PWS patients have more severe behavioral and endocrine abnormalities (Cassidy et al., 2000) . The distinction between these phenotypes is related to imprinting effects (Jiang et al., 1998) . In rare cases, the AS phenotype is caused by mutations in the maternally expressed UBE3A (E6-AP ubiquitin protein ligase) gene (Kishino et al., 1997) , while no single-gene mutations have been shown to be responsible for the PWS phenotype.
Presumably LCRs flanking the AS/PWS region (i.e., partially duplicated paralogs of the HERC2 gene, END repeats) are thought to mediate the rearrangements seen in AS/PWS patients (Amos-Landgraf et al., 1999) . Additionally, END repeats and LCR15s ) also mediate formation of isodicentric chromosome 15s or idic(15) (Robinson et al., 1993; Battaglia, 2005) , also formerly known as inverted duplication 15, and 15q11-q13 interstitial duplication rearrangements or dup(15) (Browne et al., 1997; Repetto et al., 1998) . The clinical outcomes of these syndromes are dependent on (1) the inclusion of the AS/PWS w4 Mb critical region in the rearranged segment, (2) parent of origin for the rearrangement, and (3) in the case of idic(15), the ploidy of the isodicentric chromosome. It is evident that the AS/PWS critical region contains genes important for development, cognition, speech and language, behavior, and other neurological functions, and that the chromosome 15q11-q13 region is highly unstable and susceptible to LCR-mediated genomic rearrangement and CNV-causing disease.
Miller-Dieker Syndrome and Lissencephaly
Miller-Dieker syndrome (MDLS; OMIM # 247200) is a neurodevelopmental disorder mediated by microdeletion of 17p13.3, and is a contiguous gene syndrome (CGS) including the LIS1 (lissencephaly-1) gene (Dobyns et al., 1993) . CGSs are a group of clinically recognizable disorders characterized by duplication or deletion of a chromosomal interval spanning multiple contributory genes (Shaffer et al., 2001) . MDLS is characterized by the brain malformation lissencephaly (LIS), dysmorphic facial features, mental retardation, epilepsy, spasticity, and reduced longevity (Dobyns et al., 1993) . A milder form without dysmorphic facial features and with a less-severe grade of LIS is considered as isolated lissencephaly sequence (ILS). Compared to patients with ILS, those with MDLS have larger deletion intervals (R1.3 Mb) and show a more severe grade of LIS, likely due to the inclusion of particular genes other than LIS1 in the deletion interval (Cardoso et al., 2003) . Although a complete in silico analysis for LCRs in this region has not been formally documented, candidate LCRs which may cause susceptibility and genomic instability resulting in these nonrecurrent rearrangements are present (UCSC Genome Browser, http://genome.ucsc.edu/). Smith-Magenis Syndrome and Its Reciprocal Duplication Smith-Magenis syndrome (SMS; OMIM #182290) is a CGS caused most frequently by recurrent microdeletions of 3.7 Mb on 17p11.2 and less frequently by nonrecurrent (atypical) deletions (Greenberg et al., 1991; Chen et al., 1997; Shaw et al., 2004b; Shaw and Lupski, 2005; Bi and Lupski, 2006) . SMS is characterized by specific neurobehavioral anomalies, sleep disturbance, craniofacial anomalies, and brachydactyly in addition to developmental delay and variable mental retardation (Greenberg et al., 1991 (Greenberg et al., , 1996 Finucane et al., 1994; Chen et al., 1996; Dykens and Smith, 1998; Bi and Lupski, 2006; Goldman et al., 2006; Gropman et al., 2006; Madduri et al., 2006) . The reciprocal 3.7 Mb common microduplication syndrome dup(17)(p11.2p11.2) causes a milder phenotype (Potocki et al., 2000) . The recurrent rearrangements of 17p11.2 occur by meiotic NAHR Bi et al., 2003) mediated by SMS-REP LCRs (Chen et al., 1997; Park et al., 2002) , whereas the nonrecurrent rearrangements occur by both homologous (NAHR) and nonhomologous (NHEJ) mechanisms (Shaw and Lupski, 2005) .
Haploinsufficiency for the RAI1 and Rai1 (retinoic acid-induced) genes which function in neuronal and organ development in humans and mice, respectively (Imai et al., 1995; Bi et al., 2005) , is coupled with most features of SMS Girirajan et al., 2005) ; RAI1 point mutations have been identified in SMS patients without deletion (Slager et al., 2003; Bi et al., 2004; Girirajan et al., 2005; Bi and Lupski, 2006; Bi et al., 2006) . Patients with larger deletions have a more severe phenotype (Madduri et al., 2006) , including peripheral neuropathy, because these deletions extend into the dosage-sensitive PMP22 gene that causes HNPP when haploinsufficient (Trask et al., 1996) . Experiments in chromosome-engineered mouse models for dup(17)(p11.2p11.2) syndrome (Walz et al., 2003 , suggest that normal disomic Rai1 gene dosage is sufficient to rescue the majority of complex physical and behavioral phenotypes observed in Dp(11)17/+ mice . Neurofibromatosis Type 1 Mediated by Microdeletion of 17q11.2 Recurrent interstitial microdeletions of w1.5 Mb including the NF1 tumor-suppressor gene are found in 5%-20% of patients with autosomal dominant Neurofibromatosis type 1 (NF1; OMIM +162200) (Cnossen et al., 1997; Rasmussen et al., 1998) . NF1 is a highly variable disorder; the signs and symptoms may begin at birth and evolve over time and may be divided into tumor (Theos and Korf, 2006) and nontumor manifestations. The latter include variable deficits in cognition, learning and memory, and attention (North et al., 1997; Zoller et al., 1997) . NF1 gene deletions produce a more severe phenotype than point mutations (Leppig et al., 1997; De Raedt et al., 2003) , suggesting that complete loss of gene function is more pathogenic and that dosage-sensitive genes surrounding NF1 may influence ultimate clinical outcome (i.e., by position effect or by physical inclusion in the deletion).
This recurrent contiguous gene deletion (type I), which encompasses NF1 and at least 13 other genes, occurs via NAHR with rearrangement hot spots contained within the NF1REP-P1 and NF1REP-M LCRs (Dorschner et al., 2000; Jenne et al., 2001; Ló pez-Correa et al., 2001; Forbes et al., 2004) . A smaller, recurrent, somatic microdeletion (type II) causing ''segmental'' NF1 accounts for fewer (25%) NF1 microdeletions, which are mediated by the JJAZ1 gene and JJAZ1 pseudogene (J) during mitosis (Kehrer-Sawatzki et al., 2004) .
Rearrangements of 22q with a Range of Cognitive and Psychiatric Phenotypes
CNVs have also been found on chromosome 22, particularly on the q11 and q13 bands. Deletion of 22q11.2 causes DiGeorge (DGS; OMIM #188400)/velo-cardio-facial syndrome (VCFS; OMIM #192430), also referred to as 22q11.2 deletion syndrome (22q11DS), while atypical deletions (Rauch et al., 2005) distal to the commonly deleted region and duplication of 22q11.2 cause clinically distinct syndromes. VCFS is associated with developmental delay and a wide range of cognitive and neurological deficits, including that of speech, language, memory, and attention (Lynch et al., 1995; Moss et al., 1999; Bearden et al., 2001; Woodin et al., 2001; El Tahir et al., 2004) . Intriguingly, 15%-20% of individuals with VCFS due to this 22q11.2 deletion were found to have schizophrenia (Murphy and Owen, 2001; Murphy, 2002) , suggesting that there may be a link between genes in this region and psychiatric disorders.
The 3 Mb deletion causing VCFS contains the COMT (catechol-O-methyltransferase; Shashi et al., 2006) and TBX1 (T box transcription factor 1; Paylor et al., 2006) genes. CNV of these genes has been implicated in the cognitive and behavioral phenotypes associated with VCFS. The breakpoints of the common recurrent deletion are associated with three of the eight LCR22s found in this region (Edelmann et al., 1999a; Shaikh et al., 2000) and one particular Alu sequence (Uddin et al., 2006) .
The clinical presentation of microduplication 22q11.2 syndrome (OMIM #608363) is highly variable, ranging from extremely mildly affected individuals with behavioral abnormalities to individuals with multiple defects, only some of which are similar to VCFS (Edelmann et al., 1999b; Yobb et al., 2005) . These duplications range from w3 Mb (common) to w4 Mb and w6 Mb within the 22q11.21-q11.23 chromosome region, and the breakpoints also appear to be associated with LCR22s (Edelmann et al., 1999b; Ensenauer et al., 2003) . One case of triplication (i.e., resulting in four copies of this region) has also been identified (Yobb et al., 2005) . LCR22s have also been shown to alter the dosage of 22q11 by mediating (1) an (11;22) translocation causing the der(22) syndrome and (2) the formation of a supernumerary chromosome resulting in Cat-Eye syndrome (CES; OMIM#115470; McDermid and Morrow, 2002) .
Patients with 22q13 deletion syndrome, or PhelanMcDermid Syndrome (OMIM #606232), present with global developmental delay, hypotonia, absent or delayed speech, mental retardation, and normal to advanced growth, in addition to some autistic and minor dysmorphic features (Phelan et al., 2001 ). The deletions, ranging from 100 kb to 9 Mb, are mostly paternal in origin (Anderlid et al., 2002; Luciani et al., 2003; Wilson et al., 2003) . CNV causing haploinsufficiency of the SHANK3/ PROSAP2 gene (Boeckers et al., 1999a (Boeckers et al., , 1999b Naisbitt et al., 1999) , which encodes for a structural protein of the postsynaptic density, may be causative for the associated neurological symptoms (Wilson et al., 2003) . X Chromosome CNV and Neurodevelopmental Disorders CNVs on the X chromosome have also been found to be responsible for several disease-causing traits, the observed sex-differences of which may be due to X inactivation in females and hemizygosity in males. Rett syndrome (RTT; OMIM #312750), which primarily affects females, is caused most often by loss-of-function mutations in the MECP2 (Methyl CpG binding protein 2) gene on chromosome Xq28 (Amir et al., 1999) , and less frequently by genomic deletion (Ravn et al., 2005) . Consistent with a dosage-dependent role for MECP2, gains in copy number for a region spanning MECP2 have been reported in boys with severe mental retardation and progressive neurological symptoms (i.e., spasticity and seizures; Meins et al., 2005; Van Esch et al., 2005; del Gaudio et al., 2006) . The MECP2-overexpression mouse model gives a similar neurological phenotype (Collins et al., 2004) .
The sizes of the duplications range from 200 kb to 2.2 Mb, and five critical genes found within the minimal duplication region reported include L1CAM through MECP2 (Meins et al., 2005; Van Esch et al., 2005; del Gaudio et al., 2006) . The phenotypic severity appears to correlate with increased MECP2 gene dosage rather than with duplication size. A complex array of variously oriented LCRs (LCR-MECP2s) are found scattered throughout an w4 Mb region flanking MECP2, suggesting the potential involvement of these LCRs in these rearrangements ( Figure 2A ; del Gaudio et al., 2006) .
CNV of the PLP1 (proteolipid protein 1) locus is responsible for the dysmyelinating disorder PelizaeusMerzbacher disease (PMD; OMIM #312080; Gencic et al., 1989) . X-linked recessive inheritance of nonrecurrent PLP1 gene duplications accounts for the majority of PMD cases (60%-70%; Sistermans et al., 1998) , while most of the remaining cases are due to point mutations and deletions. Genomic rearrangements causing a position effect were also reported as a potential fourth mutational mechanism (Muncke et al., 2004; Lee et al., 2006b) .
PMD manifests as a spectrum of diseases affecting the CNS, from severe early-onset encephalopathy due to missense mutations, to a classic form which is present in patients with PLP1 duplication, to a more mild form which includes the PLP1 gene-deletion phenotype characterized by peripheral and central neuropathy, and the later-onset allelic disorder spastic paraplegia type 2 (SPG2; OMIM #312920; Johnston and Mc Kusick, 1962; Saugier-Veber et al., 1994) . Classic PMD patients generally present with nystagmus, spastic quadriplegia, ataxia, and developmental and cognitive delay (Garbern et al., 1999) . A cellular trafficking defect arises from dosage alteration of PLP1, affecting disease pathogenesis and severity (Southwood and Gow, 2001) .
While duplications and deletions of PLP1 are nonrecurrent, most share a similar distal breakpoint near LCR-PMDA and B (Inoue et al., 2002; Woodward et al., 2005; Lee et al., 2006a) , which are among a multitude of LCR-PMDs in the w3 Mb region flanking PLP1 ( Figure 2B ; Lee et al., 2006a) . Thus far, CNV by PLP1 duplication is consistent with a coupled homologous and nonhomologous mechanism (Woodward et al., 2005; Lee et al., 2006a) . Deletions are thought to occur by submicroscopic X to autosome translocation, Alu-Alu recombination, and NHEJ (Inoue et al., 2002) .
On the long arm of the X chromosome (Xq26.3) is the SOX3 (SRY-related HMG box 3) gene (Stevanovic et al., 1993) , which may be important for normal cognitive function and language/speech development (Rousseau et al., 1991; Laumonnier et al., 2002) . Whereas the precise role of SOX3 in cognitive function is still somewhat unclear (Woods et al., 2005) , CNV of this gene may be responsible for a speech disorder. Recently, a 7.5 Mb duplication of Xq26.2-q27.1 encompassing or disrupting the SOX3 gene was reported in affected female family members with short stature, dysmorphic features, and speech defects with stuttering and dyslalia; hearing impairment, seizure, and nystagmus were variable .
Neurodegenerative Disorders
Neurodegenerative disorders are generally caused by mutations acting over a long period of time in nonregenerating tissue. Thus, the course of these disorders is a progressive and irreversible degeneration of the affected neurons and glial cells with a later onset of clinical manifestations. Neurodegenerative disorders affect brain function and can be divided into two types: those conditions causing problems with movement, and those affecting memory/dementia. There are a number of neurodegenerative diseases that can be caused by genomic rearrangement, a few examples of which we discuss below and summarize in Table 2 . SMN1 Gene Dosage and Spinal Muscular Atrophy Spinal muscular atrophy (SMA) is a common autosomal recessive disorder characterized by degeneration of the anterior horn cells of the spinal cord leading to weakness/wasting of voluntary muscles. SMA is caused by homozygous absence of the telomeric SMN1 (survival motor neuron gene 1, or SMN T ) gene on chromosome 5q13 (Lefebvre et al., 1995) . SMA can be divided into four types: SMA I (OMIM #253300) is the most severe, including hypotonia; SMA II (OMIM #253550) is intermediate; SMA III (OMIM #253400) is mild; SMA IV (OMIM#271150) has an adult onset. All types are characterized by varying degrees of proximal muscle weakness inversely correlated with age of onset, and life expectancies are drastically shortened with increasing disease severity. In approximately 95% of patients, homozygous functional absence of the SMN1 gene due to deletion of exons 7 and 8 or gene conversion to centromeric SMN2 (SMN C , distinguishable from SMN T by one critical nucleotide difference in exon 7), for which only 10% of transcripts are processed correctly to form a product identical to SMN1, is pathogenic (Burghes, 1997) . Interestingly, increased SMN2 copy-number and gene conversion events are correlated with a milder, later-onset clinical phenotype (Mazzei et al., 2004; Wirth et al., 2006) . a-Synuclein Gene Dosage and Parkinson's Disease Parkinson's disease (PD; OMIM #168600) is the second most common neurodegenerative disease next to Alzheimer's disease (see below). Of the six causative genes that have been identified for familial PD, the SNCA (a-synuclein) gene on chromosome 4q21 has been implicated in the rare form of autosomal dominant PD (Polymeropoulos et al., 1997) . In addition, variability within the SNCA promoter is associated with an increased risk of PD, again suggesting that dosage or proper expression of the gene is critical to function (Maraganore et al., 2006) . a-Synuclein is a small synaptic protein found to be a major component of Lewy bodies (LBs) and Lewy neurites, which are the pathologic hallmarks of sporadic PD and dementia with LBs (DLB), and glial cell cytoplasmic inclusions (Spillantini et al., 1997; Tu et al., 1998) . In fact, it has been proposed that familial and sporadic PD may share common pathways (Nishioka et al., 2006) . a-Synuclein-overexpressing mice have also been shown to recapitulate the PD phenotype (Masliah et al., 2000) .
Constitutional genomic gains in SNCA copy number have been shown to be causative for PD, and it appears that dosage of this gene plays a major role in disease severity (Eriksen et al., 2005) . In particular, triplication of SNCA encompassing 1.61 to 2.04 Mb causes a severe form of PD distinguished by early onset, severe disease progression, early dementia, early autonomic failure, cerebellar signs, variable LB disease, neuronal loss in the hippocampus, and neurodegeneration beyond the substantia nigra (Polymeropoulos et al., 1997; Singleton et al., 2003; Farrer et al., 2004) . However, the phenotype associated with SNCA duplications (w220 to 394 kb) is consistent with late-onset idiopathic PD without the atypical features seen with triplication (Chartier-Harlin et al., 2004; Ibá ñ ez et al., 2004; Nishioka et al., 2006) . Thus, SNCA copy number and a-synuclein protein level regulation appear to be significant factors contributing to PD phenotypes. It has also been proposed that the size of the genomic copy-number gain may also influence the phenotype (Nishioka et al., 2006) . Amyloid Precursor Protein Gene Dosage and Alzheimer's Disease Germline duplication of the b amyloid locus APP (amyloid precursor protein) on chromosome 21q21 causes autosomal dominant early-onset Alzheimer's disease (ADEOAD; AD, OMIM #104300) associated with hereditary dementia and cerebral amyloid angiopathy (CAA) with a frequency of 8% (Rovelet-Lecrux et al., 2006) . AD is characterized by intracellular neurofibrillary tangles (NFT) and extracellular amyloid plaques that accumulate in the brain (Sennvik et al., 2000) . It has been suggested that overexpression of APP peptides may promote plaque accumulation by shifting the Ab42/ Ab40 ratio (Cabrejo et al., 2006) . Additionally, mutations in the APP promoter resulting in a neuron-specific increase in APP expression have been associated with AD (Theuns et al., 2006) . ADEOAD with CAA is also found in individuals with Down's syndrome (DS; OMIM #190685), who are at risk to develop the neuropathologic features of AD with an early onset, supporting the concept that gene dosage for this locus is causative of AD. In a trisomic mouse model of DS, increased App expression was found to disrupt nerve growth factor (NGF) transport and cause degeneration of cholinergic neurons (Salehi et al., 2006) . Nonrecurrent APP genomic duplications were reported to range in size from 580 kb to 6.37 Mb (Rovelet- Lecrux et al., 2006) , and in our independent analysis of a 13 Mb genomic region surrounding the APP locus, including PRSS7 through GRIK1 genes, a few LCRs (LCR-ADs) are present ( Figure 2C ). These LCRs could potentially stimulate rearrangements found in these Alzheimer's patients in a manner similar to what has CMT is the most common inherited disorder of the PNS (Skre, 1974) , and patients with CMT1 exhibit symmetric, moderately to severely reduced motor nerve conduction velocities with absent muscle stretch reflexes (Kaku et al., 1993) . Clinical symptoms usually present in the first or second decade of life, including progressive weakness of distal limb muscles, causing a characteristic gait abnormality, and hand muscle weakness which occurs late in the disease progression (Garcia, 1995) . HNPP is a clinically distinct, rare, slowly progressive neuromuscular disorder characterized by recurrent acute peripheral nerve palsies (Windebank, 1993; Chance and Dyck, 1998; Pareyson et al., 1998; Andersson et al., 2000; Li et al., 2004) . Patients with HNPP have periodic episodes of numbness, muscle weakness, and muscle atrophy due to demyelination, and variable palsies or peripheral nerve trauma (Earl et al., 1964) .
CMT1A is caused by duplication of the PMP22 locus in 70% of CMT1 patients. Meiotic NAHR mediated by CMT1A-REP LCRs causes PMP22 CNV Chance et al., 1994; Reiter et al., 1997 Reiter et al., , 1998 . The first NAHR recombination hot spot was identified within CMT1A-REP (Reiter et al., 1996) , and recent analysis of sequence variation at CMT1A-REPs revealed that an allelic homologous recombination (AHR) hot spot was coincident with an NAHR hot spot (Lindsay et al., 2006) . The human genome is punctuated by recombination hot spots and cold spots; however, the physical basis of both NAHR and AHR hot spots remains to be elucidated (Lupski, 2004) . Depending on if there are too many or too few copies of PMP22, CNV of this single gene causes very different phenotypes, likely through its affect on Schwann cell proliferation (Hanemann et al., 1998) . Consistent with the dosage hypothesis, patients with homozygous duplication generally manifest a more severe phenotype Kaku et al., 1993) .
Subtle dosage changes depending on the combination of gain-of-function and loss-of-function alleles of PMP22 can result in a spectrum of dosage-related phenotypes (Figure 3 ). For example, whereas heterozygous duplication of PMP22 causes CMT1A, homozygous duplication causes a more severe CMT1A phenotype. PMP22 gain-of-function point mutations can also cause CMT1A (Valentijn et al., 1992; Roa et al., 1993) , whereas frameshift or nonsense alleles cause HNPP consistent with a haploinsufficiency disease. Interestingly, the partial loss-of-function T118M PMP22 mutation can not only mitigate the effects of PMP22 duplication, but it can also result in an HNPP phenotype when paired with a normal allele (Shy et al., 2006;  Figure 3) .
As in the case for CMT1A, another-adult onset neurologic disease, autosomal dominant leukodystrophy (ADLD; OMIM %169500), has been shown recently to result from genomic duplication of a dosage-sensitive Figure 3 . Subtle Changes in PMP22 Gene Copy Number Affect CMT1A/HNPP Phenotype and Disease Severity DNA in the left panel is denoted by solid black lines, and parentheses designate a genomic interval containing a dosage-sensitive gene (square). A wild-type allele is designated as ''+''. Gain-of-function (GOF) mutations can be caused by duplication (dup) or point mutation (blue asterisk). Loss-of-function (LOF) mutations can be caused by deletion (del) or point mutation (red asterisk). The number of PMP22 gene copies is shown for each genotype, as well as the corresponding phenotype. An example given for a LOF mutation is T118M.
gene, LMNB1 (Lamin B1), critical to maintenance of the nervous system (Padiath et al., 2006;  Table 2 ).
Psychiatric Disorders
Psychiatric/psychological disorders are to some degree influenced by both genetic and environmental factors. These conditions include mental illnesses characterized by the impairment of an individual's normal cognitive, emotional, or behavioral functioning. They are challenging to ascertain and treat clinically because of the intricate nature of human behavior, and they are problematic for researchers because of genetic heterogeneity, incomplete penetrance of psychiatric traits, and nonMendelian inheritance of complex traits. The genetics and genomics of behavioral and psychiatric disorders has been reviewed recently (Inoue and Lupski, 2003) . While genome-wide association studies have drawn attention to certain chromosome regions with respect to psychiatric disease, progress has been limited in terms of identifying disease-associated alleles prevalent in the general population. Conversely, rare individuals or families with psychiatric disease who are found to have cytogenetic rearrangements can potentially reveal disease-associated loci (Millar et al., 2000 (Millar et al., , 2005 Kamnasaran et al., 2003) . Below, we discuss several instances in which psychiatric disorders are found to be associated with genomic rearrangements, suggesting that copy number of still-undetermined dosagesensitive genes is altered (Table 3) .
Chromosome 4 has proven to be a good candidate for mood disorders and affective disturbances in several independent studies (Fullerton et al., 2003; Middleton et al., 2004; Ramanathan et al., 2004) . Recently, a rare case of de novo maternal uniparental isodisomy of chromosome 4 (UPD4) was reported in which the female proband had a mild phenotype characterized by major depressive disorder (MDD) associated with suicide attempts (Middleton et al., 2006) . This is the third reported case of UPD4 (Lindenbaum et al., 1991; Spena et al., 2004) but the first case associated with a mood disorder. Since one of the other reported cases also involved maternal UPD, it is likely that the UPD4 in this proband is causative for her MDD, through a mechanism of homozygosity for a maternal recessive allele.
Genome-wide scans have revealed strong linkage for a causative gene for bipolar disorder to a distal region of chromosome 8q (Cichon et al., 2001; Dick et al., 2003; Liu et al., 2003; McInnis et al., 2003; Avramopoulos et al., 2004; McQueen et al., 2005) . Interestingly, a single case study reported a male patient with bipolar disorder and speech delay who was found to have duplication of 8q22.1-q24.1 due to an unbalanced translocation and partial trisomy of 8q (Macayran et al., 2006) . The patient's phenotype includes ADHD, impulsivity, pressured speech, delayed language, sleep disturbance, aggression, and hypersexuality; neurological examination was normal but deficits in fine motor and social skills were noted, as well as an unconfirmed family history of mood disorders (Macayran et al., 2006) . Partial chromosome 8q trisomy, potentially including dosage-sensitive genes important for normal brain function, may be responsible for the patient's psychiatric phenotype (Macayran et al., 2006) .
Another informative patient with bipolar affective disorder and duplication of chromosome 15q14/pter, and thus partial trisomy 15, has been followed longitudinally for over 15 years (Reif et al., 2004) . This patient also presents with dysmorphic features, positive pyramidal tract signs, hypotonia, awkward movements, and intellectual impairment (Reif et al., 2004) . Interestingly, trisomy 15 mosaicism is known to cause a PWS phenotype, which is often characterized by cycloid psychosis and bipolar affective disorder (Liu et al., 2001 ). The abnormal expression of an imprinted gene underlying psychotic illness in PWS possibly may account for the bipolar phenotype in duplication 15q14/pter, or this rearrangement could represent a distinct clinical entity. Intriguingly, chromosome 15q13-q15 has been implicated independently as a susceptibility locus for schizophrenia (Stö ber et al., 2000; Liu et al., 2001) , and in Andermann's syndrome, which is associated with progressive peripheral neuropathy, agenesis of the corpus callosum, and some psychotic features (Casaubon et al., 1996) .
Whether there is a genomic susceptibility factor for panic and phobic disorders on chromosome 15 is a subject of debate. An interstitial duplication of chromosome 15q24-q26 was identified as a polymorphism in a study population, and this CNV (DUP25) was found to be significantly associated with panic/agoraphobia/social phobia/joint laxity and panic disorder . Gratacò s et al. identified two different types of DUP25 by fluorescence in situ hybridization (FISH) in 72% of patients with panic disorder tested, but with incomplete penetrance (80%), whereas the frequency of DUP25 in the general population was found to be 7% . Flanking the DUP25 region are LCR15 sequences ) which may mediate the duplication, a rearrangement which is proposed to be mitotic in origin and inherited in a non-Mendelian fashion . However, several independent investigators have not been able to detect DUP25 in the same and other cohorts of anxiety-disorder patients and have thus been unable to confirm an association between DUP25 and anxiety disorders (Hollox and Armour, 2003; Schumacher et al., 2003; Tabiner et al., 2003; Weiland et al., 2003; Henrichsen et al., 2004; Vermeulen et al., 2004; Zhu et al., 2004) .
Copy-Number Variation in the General Population
CNV is unexpectedly prevalent in the genomes of normal individuals in population-based studies (Iafrate et al., 2004; Sebat et al., 2004; Rendon et al., 2006) , with a cumulative total of 1296 CNVs covering approximately 143 Mb of sequence (http://projects.tcag.ca/variation; Freeman et al., 2006). These CNVs appear for the most part to be heritable with only modest linkage disequilibrium (LD) with SNPs (Locke et al., 2006) . This modest LD may be due to (1) poor SNP coverage in complex regions, (2) high error rate for genotyping CNVs, (3) high recombination rate in regions of CNV, or (4) high rate of spontaneous recurrence of CNVs. CNV has been found to account for a substantial amount of genetic variation between individuals, and it may account for a significant portion of normal phenotypic variation (Freeman et al., 2006) , such as normal behavioral differences or an individual's disease susceptibility (Nadeau and Lee, 2006) . Furthermore, CNV is not confined to a single population group, indicating that either these variants were present early in human history, or that they are highly recurrent events (Sharp et al., 2005) . Because of the prevalence of CNV in the human population, the concept of a ''normal copy number'' of a given gene or genomic region has thus, in some cases, become unclear (Axton, 2006) . Duplications and deletions affecting the copy number of certain genes may often act as benign euchromatic variants (i.e., without phenotypic effect; Barber et al., 1998; Engelen et al., 2000) . However, CNV of dosagesensitive genes which have a function(s) in the nervous system, such as PMP22, PLP1, RAI1, and others discussed herein, have direct clinical outcomes which may present early-on or may act over a long period of time through a multitude of mechanisms (i.e., protein trafficking or accumulation, neuronal differentiation, etc.). Thus, in addition to single-nucleotide and coding-region changes, alteration of gene copy number or dosage and expression may produce phenotypic effects. Aside from CNV, other proposed molecular mechanisms by which genomic rearrangements can potentially alter gene dosage and expression and thereby convey a phenotype include gene interruption, gene fusion, position effect, unmasking a recessive allele or functional polymorphism, and possibly disruption in regulatory interactions between chromosomes by a transvection effect .
Copy-Number Variation and Higher-Order Genomic Architecture
Higher-order genomic features have been suggested to function in mediating (or stimulating) normal variation in the human genome. Using array comparative genomic hybridization (CGH) technology to assess CNV in putative rearrangement-hot spot regions flanked by a certain subclass of LCRs in the normal population, a 4-to 5-fold enrichment of CNV was observed compared to control regions (Sharp et al., 2005) , similar to the high number of SNPs previously reported within LCRs (Bailey et al., 2002) , such as CMT1A-REP Lindsay et al., 2006) . Furthermore, Sharp et al. found an enrichment of rearrangement-hot spot sequences within the more frequently occurring CNVs. Accordingly, a strong link has been established between higher-order genomic architecture and CNV in the human genome (Iafrate et al., 2004; Sebat et al., 2004) . CNV has been identified in regions which are generally not gene poor (Sharp et al., 2005) and may include genes for which dosage is critical. Thus, LCRs may play an important role both in normal structural variation and in CNV causing genomic disorders.
Copy-Number Variation and Complex Traits
Some of the neurologic disorders discussed above are single-gene disorders, but many are single-locus CGS, including WBS, PWS, and 22q11DS, to name a few. Several of these disorders present with distinct behavioral, psychological, and physical phenotypes. The existence of these complex characteristic traits observed in individuals with particular genomic rearrangements lends support to the concept that these traits are to some extent genetically determined. Thus, structural genomic changes, or CNV of a gene(s) contained within the rearranged segment, may be directly responsible for the associated phenotype. It is not a major leap to hypothesize that other CNVs could account for behavioral or psychological variations among individuals in the general population.
The partial overlap in the disease traits observed for the selected neurologic disorders discussed herein can be appreciated. For example, some common features include developmental delay, cognitive and visuospatial construction deficits, autistic features, hypotonia, and dysmorphic features, among others. While the complex traits associated with some genomic disorders may be a general property of higher-level changes in brain architecture or neuronal connections that could be common to a number of disparate deletion or duplication syndromes, others may be assigned to one specific gene. And while susceptibility to HIV, lupus with glomerulonephritis, and Crohn's disease has recently been linked to CNV of CCL3L1, FCGR3B, and HBD-2 genes, respectively (Gonzalez et al., 2005; Aitman et al., 2006; Fellermann et al., 2006) , there are many conditions and CGS disorders for which the causative gene(s) has not yet been determined. Future studies of CNV in relation to complex human genetic disease traits will bring us toward the identification of specific dosagesensitive genes important for neurocognitive skills/ deficits, personality determinants, behavioral abnormalities, and psychiatric disorders. CNV can now be considered, along with single-nucleotide and coding-region changes, as an important factor contributing to human variation, disease, and complex traits.
Heritability of Behavioral and Personality Traits
Not only have constitutional (as opposed to somatic) CNVs been found to be heritable, but behavioral, personality, and psychiatric traits themselves have been found to potentially have a large genetic component (Tellegen et al., 1988; Plomin, 1990; Bouchard, 1994; McGue and Bouchard, 1998) . In fact, genetic factors may account for at least half of the variability in personality (Tellegen et al., 1988) . In studies measuring the concordance between monozygotic (MZ) versus dizygotic (DZ) twins, the results were approximately 2-fold higher for MZ twins for most behavioral disorders (McGue and Bouchard, 1998) . It is possible that almost all individual psychological differences are substantially heritable (Bouchard and McGue, 2003) . From studies of identical twins reared together versus apart, it was concluded that human behavior has little influence from a shared environment (Tellegen et al., 1988) , except perhaps for cognitive ability, juvenile delinquency, and antisocial behavior traits (Chipeur et al., 1990; Bouchard and McGue, 2003) . In general, the only significant environmental influence on behavior may be from an unshared environment (McGue and Bouchard, 1998) , but this influence is likely far overshadowed by the substantial genetic factor.
The concept of population-specific behaviors has gotten some recent attention. It was found that based on a five-factor model (McCrae and John, 1992) , individuals believe that members of their respective cultures globally possess certain personality traits more than others. It was determined by extensive objective testing that while their aggregate descriptions of cultural perceptions revealed distinct personality differences across cultures, these differences did not reveal a culture-specific personality profile and argued against any evidence for a national stereotype (McCrae and Terracciano, 2005; Terracciano et al., 2005) . However, while the validity of national stereotypes may be in doubt, selected populations scored differently on these tests , and the fact remains that personality, behavior, and psychiatric traits are largely heritable. These traits often result from the contribution of many genes, lending to the complexity of human behavior. The molecular bases of such behavioral traits remain to be determined, but CNV and gene-dosage effects are distinct possibilities. Heritable population-specific CNVs could potentially underlie some behavioral tendencies of selected world populations.
Animal Studies Suggest CNV of Select Genes Can Cause Complex Traits, Including Behavior
Experiments in chromosome-engineered mouse models demonstrate that CNV of just a single gene can be responsible for the majority of complex behavioral and physical disease traits. Using an established mouse model for dup(17)(p11.2p11.2) syndrome, or Dp(11)17/+ (Walz et al., 2003 , that recapitulates most of the phenotypes in human patients, Walz et al. (2006) attempted to explore the role of Rai1 copy number in the Dp(11)17/+ phenotype. When Dp(11)17/+ and Df(11)17/+ mice were mated, the physical and behavioral traits of Dp(11)17/Df(11)17 progeny, in which the dosage of all 19 genes in the SMS critical interval is balanced, were normalized (Figure 4) . Additionally, Rai1 +/2 mice were generated that had a phenotype similar to that of Df(11)17/+ animals , even though they were haploinsufficient for only one of the 19 SMS critical interval genes deleted in the Df(11)17/+ chromosomeengineered model (Figure 4 ). In the generation of Dp(11)17/Rai1 2 compound heterozygous animals, it was determined that restoring the copy number of Rai1 alone is sufficient to rescue the duplication phenotype, despite the trisomic copy number of the remaining 18 genes in the SMS critical interval (Figure 4) . Thus, normalizing the copy number of just a single gene is sufficient to rescue the majority of complex physical and behavioral phenotypes .
Treatment of Disorders Due to Gene Dosage
If a genomic disorder results from altered gene dosage, it may be possible to intervene therapeutically by correcting the gene dosage. Recent therapeutic strategies to treat disorders caused by CNV have been aimed at correcting gene dosage epigenetically, as opposed to physical genetic modification of the causative gene. As steroid hormones have long been known to stimulate myelination in peripheral nerves, and since PMP22 expression is regulated by steroids, Sereda et al. (2003) postulated that modulation of gene expression could be achieved through hormone therapy. In a Pmp22-overexpressing rat model of CMT1A, daily administration of progesterone elevates the levels of Pmp22 mRNA and Pmp22 protein and exacerbates the clinical neuropathy, whereas onapristone, a selective progesterone receptor antagonist, reduces Pmp22 overexpression and improves the CMT phenotype (Sereda et al., 2003) . Likewise, Passage et al. (2004) attempted to ameliorate the demyelinating CMT phenotype in a mouse model of CMT1A through the administration of ascorbic acid, a known promoter of myelination. Ascorbic acid treatment effectively reduced Pmp22 expression and either halted neurologic deterioration or improved motor performance (Passage et al., 2004) . Accordingly, future treatments aimed at epigenetically High-Resolution Genome Analysis of CNV During the last two decades, technology developments have enabled a higher-resolution analysis of the human genome, not only for research purposes but also in clinical diagnostic testing for disease-causing CNVs. The diagnosis of genomic rearrangements has seen a shift from cytogenetic techniques such as G-banding to molecular techniques including locus-specific FISH, chromosome painting (Schrock et al., 2006) , and telomere FISH (Flint and Knight, 2003) . Pulsed-field gel electrophoresis (PFGE), used to detect a rearrangement-specific junction fragment for common rearrangements within a size range (>25 kb and <5 Mb) not detectable by previous technologies, is now considered time-and labor-intensive compared with new technologies. Recently, array CGH using BAC and PAC genomic clones as well as multiple oligonucleotide array platforms have been successfully used to identify genomic deletions and duplications (Bruder et al., 2001; Veltman et al., 2003; Sebat et al., 2004; Shaw et al., 2004a; Cheung et al., 2005; Lee et al., 2005; Ming et al., 2006; Rendon et al., 2006; Wirtenberger et al., 2006) . This technology enables a higher throughput than FISH and PFGE and may be especially useful in identifying new genomic disorders or in detecting submicroscopic rearrangements not visible by routine chromosome analysis (Vissers et al., 2003) . Both genome-wide tiling resolution arrays and targeted arrays designed using an informed approach based on NAHR mechanisms have recently enabled the identification of new genomic disorders associated with recurrent rearrangements (Koolen et al., 2006; Sharp et al., 2006; Shaw-Smith et al., 2006) . Targeted quantitative real-time and semiquantitative PCR and multiplex ligation-dependent probe amplification (MLPA) methodologies following array CGH have also proven useful for higher-resolution mapping of regions of CNV (Koolen et al., 2006; Lee et al., 2006b; Wilson et al., 2006) . Based on our current understanding of genome architecture and susceptibility to nonrecurrent DNA rearrangements (Figure 2) , targeted arrays could potentially be designed to identify regions of CNV flanked by LCRs that likely stimulate rearrangement through a mechanism of NHEJ instead of NAHR.
Summary
Neurodevelopmental and neurodegenerative disorders can be caused by LCR-mediated/stimulated genomic rearrangements resulting in altered gene dosage or CNV. Psychiatric disorders, including mood and anxiety disorders, have also been associated with genomic rearrangements. These rearrangements result in the altered copy number, either too many or too few, of a dosage-sensitive gene(s) contained within the rearranged genomic interval. Such structural alterations to the genome, as opposed to single-nucleotide or coding-region changes, can clearly result in a variety of neurologic conditions and specific yet complex behavioral traits, either due to CNV of a contiguous set of genes or from CNV of just a single gene that has some function in the nervous system. To further dissect these structural changes, while duplication or deletion size sometimes lends severity to the clinical phenotype (i.e., PMD and SMS), additional genomic gains or gene copy numbers (i.e., PMP22 homozygous duplications, SNCA and MECP2 triplications) often contribute more to disease severity than does the rearrangement size. As is the case for SMS and the reciprocal dup(17)(p11.2p11.2) syndrome and the mouse models for these conditions, it is possible that the majority of physical and behavioral signs associated with other contiguous gene neurological and behavioral phenotypes could instead be due to CNV of only a single gene.
When a genomic rearrangement is common, recurrent, and has clustered breakpoints, NAHR mediated by region-specific LCRs is the prevailing mechanism. Nonclustered rearrangement breakpoints have been observed for nonrecurrent rearrangements; however, they can be mediated by homologous or nonhomologous (NHEJ) mechanisms. Whereas the rules for NAHR-driven recurrent genomic rearrangements have begun to be understood, the molecular mechanisms for nonrecurrent rearrangements remain rudimentary.
Regarding the rearrangements resulting in CNV and causing the neurodevelopmental and neurodegenerative diseases discussed herein, the majority of rearrangement breakpoints are found to be in the vicinity of LCRs or other repeated genic sequences. An association has in fact been established between LCRs and regions of CNV. However, direct experimental evidence by sequencing the products of recombination at the breakpoints remains to be established for CNV. Aside from the widespread CNV found throughout the genomes of normal individuals (i.e., normal structural variation), CNV of dosage-sensitive genes, in this case those that serve a function in the nervous system, results in a variety of genomic disorders. Complete LCR and breakpoint analyses for the remainder of neurologic disorders for which such analyses have not yet been performed could prove very informative for determining the molecular mechanisms for their associated genomic rearrangements resulting in CNV. Because of the surprisingly high level of CNV found in the normal population, genomic rearrangements mediated or stimulated by LCRs or other repeated genic sequences and the resulting CNV of a single gene or multiple genes important for nervous system function may potentially account for a higher proportion of heritable neurologic and psychiatric traits than is currently realized. De Raedt, T., Brems, H., Wolkenstein, P., Vidaud, D., Pilotti, S., Perrone, F., Mautner, V., Frahm, S., Sciot, R., and Legius, E. (2003) . Elevated risk for MPNST in NF1 microdeletion patients. Am. J. Hum. Genet. 72, 1288 -1292 del Gaudio, D., Fang, P., Scaglia, F., Ward, P., Craigen, W., Glaze, D., Neul, J., Patel, A., Lee, J.A., Irons, M., et al. (2006) . Increased MECP2 gene copy number due to genomic duplication in neurodevelopmentally delayed males. Genet. Med., in press. Dick, D.M., Foroud, T., Flury, L., Bowman, E.S., Miller, M.J., Rau, N.L., Moe, P.R., Samavedy, N., El-Mallakh, R., Manji, H., et al. 
